Akums Drugs has entered into a strategic partnership with a prominent global pharmaceutical company to supply specific oral liquid formulations to the European market.

The CDMO agreement is valued at approximately Rs 1,760 crore (EUR 200 million), with an upfront payment of Rs 880 crore (EUR 100 million) already secured for the project.

Sanjeev Jain, Managing Director of Akums, said, “This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”

Akums Drugs announced that the commercial supply of these formulations will commence in 2027 and continue until 2032. The company will also begin obtaining European approval for its oral formulations manufacturing facility. Akums will receive an upfront payment to support product development and site approval from regulatory authorities.

Under the agreement, Akums will manufacture and supply a “globally-renowned brand” of oral liquid formulations, which will be marketed across Europe by one of the largest multinational pharmaceutical companies. While Akums has not disclosed the client’s identity or product details, it mentioned that the partnering entity generates over $10 billion in annual revenue.

The company, in its filing, said, “The approval of the site and the product dossiers is expected to be received by 2026.”

These products are being made in Europe, and the contract is being seen as a crucial step for the company to seek other similar tie-ups. 

Sanjeev Jain, Managing Director of Akums, said, “Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust.”

The company already has a Europe-approved facility for supplying hard gelatine capsules, tablets, vials, sachets, eye drops, ampoules, and dry powder injections. 

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!